Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study)
BackgroundManagement of type 2 diabetes mellitus (T2DM) during Ramadan fasting presents unique challenges due to prolonged fasting periods, irregular meal schedules, and altered medication timing, potentially impacting glycemic control. Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1542946/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859416706842624 |
|---|---|
| author | Md Faruque Pathan Nazma Akter Marufa Mustari M. Saifuddin Mirza Sharifuzzaman Mohammad Motiur Rahman Mohammed Ripon S. M. Mohiuddin A. B. M. Kamrul-Hasan Mohammad Abdul Hannan Muhammad Shah Alam Samira Mahjabeen Faria Afsana Muhammed Abu Bakar Tahniyah Haq Afsar Ahammed Samir Kumar Talukder Sourav Sarkar Shahjada Selim |
| author_facet | Md Faruque Pathan Nazma Akter Marufa Mustari M. Saifuddin Mirza Sharifuzzaman Mohammad Motiur Rahman Mohammed Ripon S. M. Mohiuddin A. B. M. Kamrul-Hasan Mohammad Abdul Hannan Muhammad Shah Alam Samira Mahjabeen Faria Afsana Muhammed Abu Bakar Tahniyah Haq Afsar Ahammed Samir Kumar Talukder Sourav Sarkar Shahjada Selim |
| author_sort | Md Faruque Pathan |
| collection | DOAJ |
| description | BackgroundManagement of type 2 diabetes mellitus (T2DM) during Ramadan fasting presents unique challenges due to prolonged fasting periods, irregular meal schedules, and altered medication timing, potentially impacting glycemic control. Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been shown to improve glycemic control in T2DM effectively. However, the effectiveness of ertugliflozin during Ramadan fasting, a period with unique glycemic challenges, has not been studied extensively.MethodsThis study was a multicenter, real-life experience study involving 1373 adult patients with known T2DM for at least one year, an HbA1c level of less than 10%, and who intended to fast during Ramadan. Participants were divided into two groups: the Ertu group (n=703), consisting of patients who had been on a stable dose of ertugliflozin for at least three months before Ramadan, and the non-Ertu group (n=670), which included patients receiving other oral antihyperglycemic drugs (OADs) except ertugliflozin. Patients attended a baseline visit one month before the first day of Ramadan and a follow-up visit within one month after the last day of Ramadan. Both visits included history taking, physical examinations, and laboratory tests. The primary endpoints were changes in HbA1c levels, body weight, body mass index (BMI), and the incidence of hypoglycemia during Ramadan fasting.ResultsThe mean age of the study participants was 50.37 ± 11.14 (SD) years, with 40.6% male and 58.7% female. Patients receiving ertugliflozin showed significant reduction in HbA1C (-0.65 ± 0.67% vs. -0.22 ± 0.64%, p<0.001), body weight (-1.24 ± 2.58 kg vs. -0.36 ± 3.41 kg, p<0.001), and BMI (-0.48 ± 1.03 kg/m² vs. -0.11 ± 1.33 kg/m², p<0.001) compared to the non-Ertu group. Hypoglycemia was reported in 0.3% of the ertugliflozin group and 0.7% of the other group, with comparable adverse events (p=.23; ≥0.05), indicating a favorable safety profile for ertugliflozin during fasting.ConclusionThis study demonstrates that ertugliflozin is effective and safe for patients with T2DM during Ramadan fasting. |
| format | Article |
| id | doaj-art-a32d98b8aafe4abeb8a42191a67293d1 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-a32d98b8aafe4abeb8a42191a67293d12025-02-11T05:10:21ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-02-011610.3389/fendo.2025.15429461542946Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study)Md Faruque Pathan0Nazma Akter1Marufa Mustari2M. Saifuddin3Mirza Sharifuzzaman4Mohammad Motiur Rahman5Mohammed Ripon6S. M. Mohiuddin7A. B. M. Kamrul-Hasan8Mohammad Abdul Hannan9Muhammad Shah Alam10Samira Mahjabeen11Faria Afsana12Muhammed Abu Bakar13Tahniyah Haq14Afsar Ahammed15Samir Kumar Talukder16Sourav Sarkar17Shahjada Selim18Department of Endocrinology, BIRDEM General Hospital, Dhaka, BangladeshDepartment of Endocrinology, MARKS Medical College & Hospital, Dhaka, BangladeshDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, BangladeshDepartment of Endocrinology, Dhaka Medical College & Hospital, Dhaka, BangladeshDepartment of Endocrinology, Dhaka Medical College & Hospital, Dhaka, BangladeshDepartment of Medicine, Rajshahi Medical College & Hospital, Rajshahi, BangladeshDepartment of Endocrinology, Rangamati Medical College & Hospital, Rangamati, BangladeshDepartment of Endocrinology, Sir Salimullah Medical College, Dhaka, BangladeshDepartment of Endocrinology, Mymensingh Medical College, Mymensingh, BangladeshDepartment of Endocrinology, North East Medical College & Hospital, Sylhet, Bangladesh0Department of Endocrinology, Army Medical College, Cumilla, BangladeshDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh1Department of Endocrinology, Chattogram Maa O Shishu Hospital Medical College, Chattogram, Bangladesh1Department of Endocrinology, Chattogram Maa O Shishu Hospital Medical College, Chattogram, BangladeshDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh2Department of Endocrinology, National Institute of Traumatology and Orthopaedic Rehabilitation (NITOR), Dhaka, Bangladesh3Department of Endocrinology, Rangpur Medical College Hospital, Rangpur, Bangladesh4Medicine & Endocrinology, Boalkhali Upazila Health Complex, Chattogram, BangladeshDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, BangladeshBackgroundManagement of type 2 diabetes mellitus (T2DM) during Ramadan fasting presents unique challenges due to prolonged fasting periods, irregular meal schedules, and altered medication timing, potentially impacting glycemic control. Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been shown to improve glycemic control in T2DM effectively. However, the effectiveness of ertugliflozin during Ramadan fasting, a period with unique glycemic challenges, has not been studied extensively.MethodsThis study was a multicenter, real-life experience study involving 1373 adult patients with known T2DM for at least one year, an HbA1c level of less than 10%, and who intended to fast during Ramadan. Participants were divided into two groups: the Ertu group (n=703), consisting of patients who had been on a stable dose of ertugliflozin for at least three months before Ramadan, and the non-Ertu group (n=670), which included patients receiving other oral antihyperglycemic drugs (OADs) except ertugliflozin. Patients attended a baseline visit one month before the first day of Ramadan and a follow-up visit within one month after the last day of Ramadan. Both visits included history taking, physical examinations, and laboratory tests. The primary endpoints were changes in HbA1c levels, body weight, body mass index (BMI), and the incidence of hypoglycemia during Ramadan fasting.ResultsThe mean age of the study participants was 50.37 ± 11.14 (SD) years, with 40.6% male and 58.7% female. Patients receiving ertugliflozin showed significant reduction in HbA1C (-0.65 ± 0.67% vs. -0.22 ± 0.64%, p<0.001), body weight (-1.24 ± 2.58 kg vs. -0.36 ± 3.41 kg, p<0.001), and BMI (-0.48 ± 1.03 kg/m² vs. -0.11 ± 1.33 kg/m², p<0.001) compared to the non-Ertu group. Hypoglycemia was reported in 0.3% of the ertugliflozin group and 0.7% of the other group, with comparable adverse events (p=.23; ≥0.05), indicating a favorable safety profile for ertugliflozin during fasting.ConclusionThis study demonstrates that ertugliflozin is effective and safe for patients with T2DM during Ramadan fasting.https://www.frontiersin.org/articles/10.3389/fendo.2025.1542946/fulldiabetes mellitusRamadanfastingertugliflozinSGLT2 inhibitorssafety |
| spellingShingle | Md Faruque Pathan Nazma Akter Marufa Mustari M. Saifuddin Mirza Sharifuzzaman Mohammad Motiur Rahman Mohammed Ripon S. M. Mohiuddin A. B. M. Kamrul-Hasan Mohammad Abdul Hannan Muhammad Shah Alam Samira Mahjabeen Faria Afsana Muhammed Abu Bakar Tahniyah Haq Afsar Ahammed Samir Kumar Talukder Sourav Sarkar Shahjada Selim Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) Frontiers in Endocrinology diabetes mellitus Ramadan fasting ertugliflozin SGLT2 inhibitors safety |
| title | Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) |
| title_full | Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) |
| title_fullStr | Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) |
| title_full_unstemmed | Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) |
| title_short | Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study) |
| title_sort | effectiveness of ertugliflozin during ramadan fasting in patients with type 2 diabetes mellitus a real world study erturamadan study |
| topic | diabetes mellitus Ramadan fasting ertugliflozin SGLT2 inhibitors safety |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1542946/full |
| work_keys_str_mv | AT mdfaruquepathan effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT nazmaakter effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT marufamustari effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT msaifuddin effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT mirzasharifuzzaman effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT mohammadmotiurrahman effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT mohammedripon effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT smmohiuddin effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT abmkamrulhasan effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT mohammadabdulhannan effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT muhammadshahalam effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT samiramahjabeen effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT fariaafsana effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT muhammedabubakar effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT tahniyahhaq effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT afsarahammed effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT samirkumartalukder effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT souravsarkar effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy AT shahjadaselim effectivenessofertugliflozinduringramadanfastinginpatientswithtype2diabetesmellitusarealworldstudyerturamadanstudy |